Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 2 endocrinologydiseases
hyperglycemia 3 endocrinologydiseases
hyperlipidemia 5 endocrinologydiseases
metabolic syndrome 2 endocrinologydiseases
obesity 9 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
diabetes mellitus 18234 endothelial dysfunction that results from diverse cardiovascular risk factors such as hyperlipidemia, diabetes mellitus , obesity and hypertension [[61]]. NO deficiency can be caused by decreased substrate l-arginine availability,
diabetes mellitus 18734 with most of the clinical conditions associated with MetS such as hypertension, hypercholesterolemia, diabetes mellitus , obesity and NAFLD [[27]]. As reviewed elsewhere, impaired ADMA-NO pathway plays an important role in
hyperglycemia 2084 conditions including hypertension, obesity, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), hyperglycemia and insulin resistance [[2]]. Despite the recent advances in medical and surgical treatment, there is
hyperglycemia 20262 is well known that over activation of the classical RAS leads to hypertension [[65]]. Additionally, hyperglycemia and insulin resistance have been demonstrated to activate RAS components (e.g., renin, ACE and AT1R)
hyperglycemia 26515 pregnancy and lactationMaternal high-fat dietMale and female Wistar ratsN = 4–63 weeksAttenuated hyperglycemia , obesity and hyperlipidemia[[46]]Resveratrol (4 g/kg of diet) between 3–12 weeks of agePrenatal hypoxia
hyperlipidemia 16805 post-weaning resveratrol treatment activates AMPK and protects adult offspring against insulin resistance and hyperlipidemia in a combined prenatal hypoxia and postnatal high-fat diet rat model [[49]]. In agreement with this
hyperlipidemia 18218 mechanism of endothelial dysfunction that results from diverse cardiovascular risk factors such as hyperlipidemia , diabetes mellitus, obesity and hypertension [[61]]. NO deficiency can be caused by decreased substrate
hyperlipidemia 26542 lactationMaternal high-fat dietMale and female Wistar ratsN = 4–63 weeksAttenuated hyperglycemia, obesity and hyperlipidemia [[46]]Resveratrol (4 g/kg of diet) between 3–12 weeks of agePrenatal hypoxia and postnatal high-fat
hyperlipidemia 27055 agePrenatal hypoxia and postnatal high-fat dietMale SD ratsN = 612 weeksAttenuated insulin resistance and hyperlipidemia [[49]]Resveratrol (50 mg/L) in drinking water from weaning to three months of ageMaternal plus post-weaning
hyperlipidemia 27402 lactationMaternal plus post-weaning high-fat dietMale C57BL/6 J miceN = 1014 weeksPrevented obesity and hyperlipidemia [[51]]0.5% resveratrol in drinking water between 2 and 4 months of ageMaternal plus post-weaning high-fat
metabolic syndrome 25503 therapy.Figure 1Schematic representation of beneficial effects and molecular targets of resveratrol against metabolic syndrome and related disorders. ↑ = increased. ↓ = decreased. Arrow = activation. T bar = inhibition.ijms-19-02584-t001_Table
metabolic syndrome 25781 resveratrol supplementation as a reprogramming strategy in animal models of fetal programming associated with metabolic syndrome -related phenotypes.Dose and Period of Resveratrol SupplementationAnimal ModelsGender/SpeciesGroup SizeAge
obesity 2018 by MetS and related disorders [[1]]. MetS is a cluster of medical conditions including hypertension, obesity , dyslipidemia, non-alcoholic fatty liver disease (NAFLD), hyperglycemia and insulin resistance [[2]].
obesity 3951 Offspring born following famine exposure are prone to develop different phenotypes of MetS, such as obesity , diabetes and hypertension [[13],[14],[15]]. The risks for developmental programming of MetS have been
obesity 4344 Risks reported in these cohorts include: maternal malnutrition, maternal smoking exposure, maternal obesity , gestational hypertension, short-term breastfeeding, excessive postnatal weight gain and in utero exposure
obesity 9748 MetS and related disorders [[35],[36]], among these are diabetes, NAFLD, cardiovascular diseases and obesity . However, a wide range of therapeutic periods and doses of resveratrol (5 mg to 5 g) are presented in
obesity 18253 dysfunction that results from diverse cardiovascular risk factors such as hyperlipidemia, diabetes mellitus, obesity and hypertension [[61]]. NO deficiency can be caused by decreased substrate l-arginine availability,
obesity 18753 clinical conditions associated with MetS such as hypertension, hypercholesterolemia, diabetes mellitus, obesity and NAFLD [[27]]. As reviewed elsewhere, impaired ADMA-NO pathway plays an important role in the pathogenesis
obesity 26530 lactationMaternal high-fat dietMale and female Wistar ratsN = 4–63 weeksAttenuated hyperglycemia, obesity and hyperlipidemia[[46]]Resveratrol (4 g/kg of diet) between 3–12 weeks of agePrenatal hypoxia and
obesity 27390 pregnancy and lactationMaternal plus post-weaning high-fat dietMale C57BL/6 J miceN = 1014 weeksPrevented obesity and hyperlipidemia[[51]]0.5% resveratrol in drinking water between 2 and 4 months of ageMaternal plus
obesity 27724 gavage during pregnancyMaternal low protein dietMale and female Wistar ratsN = 7–1416 weeksAttenuated obesity and insulin resistance[[53]]Studies tabulated according to offspring age at evaluation; SD rats = Sprague-Dawley

You must be authorized to submit a review.